Dewpoint Therapeutics partners with Novo Nordisk to explore the field of biomolecular condensates to treat insulin resistance and diabetes progression

~ Dewpoint Therapeutics and Novo Nordisk have announced a research and development partnership to identify drug candidates using Dewpoint's discovery platform related to biomolecular condensates to treat insulin resistance and diabetic complications.

The partnership brings together Novo Nordisk's global leadership in treating diabetes and metabolic diseases with Dewpoint's groundbreaking discovery and AI technology platform to identify modulators of biomolecular condensates. The scope of the agreement includes discovering potential small molecule drugs against multiple new condensate targets that may be involved in mechanisms of insulin resistance and insulin sensitivity. Novo Nordisk can also choose to discover non-small molecule drugs against the identified condensates using internal Novo Nordisk capabilities and gains rights to further develop and commercialize such potential drugs.

Under the partnership, Dewpoint is eligible to receive up to $55 million in the near term which includes an upfront payment, research funding and potential research milestones across two programs. Dewpoint is also eligible to receive up to $690 million of clinical, commercial and sales milestones plus royalties across two commercial products. If Novo Nordisk decides to pursue other modalities for the condensates, Dewpoint will be eligible to receive up to $107.5 million in total milestones per product.

More on Boston Chron
Insulin resistance is a key driver of type 2 diabetes and metabolic syndrome, with prevalence ranging from 15.5% - 46.5% globally.[i] Insulin resistance occurs when the body has an impaired response to insulin, resulting in elevated levels of glucose in the blood which leads to diabetes and complications in other organs and tissues.

Ameet Nathwani, M.D., CEO of Dewpoint Therapeutics commented on the partnership: "Our partnership with Novo Nordisk brings together Dewpoint's cutting-edge condensate science with deep expertise from a global leader in diabetes. We believe that by discovering and hopefully reversing the dysregulation of biomolecular condensates that leads to insulin resistance, we have the potential to profoundly impact the development and clinical course of diabetes, one of the most profound global health challenges affecting society today."

Uli Stilz, Ph.D., VP Novo Nordisk Bio Innovation Hub in Cambridge, Mass added: "We are excited to explore with Dewpoint the possibilities for novel therapeutics for the treatment of diabetes. Novo Nordisk's extensive knowledge in diabetes and drug development capabilities complements Dewpoint's leading expertise in condensate biology and unique approaches to identifying potential drug candidates."

More on Boston Chron
Condensates are membraneless organelles that form dynamically throughout cells via a process called phase separation which organize molecules within cells enabling certain key biochemical processes. The dysregulation of biomolecular condensates has been observed in many diseases including diabetes; Dewpoint's platform can discover disease-driving condensates as well as develop drugs that potentially provide novel therapeutic options for complex diseases or historically undruggable targets.
Filed Under: Business

Show All News | Report Violation